Maryland's Medical Marijuana Industry to be Regulated by Alcohol and Tobacco Commission.

Dec.20.2022
Maryland's Medical Marijuana Industry to be Regulated by Alcohol and Tobacco Commission.
Maryland MMJ industry oversight to be transferred to state's alcohol and tobacco commission starting 2023. Adult-use sales legalized.

Beginning in 2023, the medical marijuana industry in Maryland, United States, will be regulated by the state's alcohol and tobacco commission.


The Marijuana Medical Commission of Maryland (MMCC) has been overseeing the state's medical marijuana industry since sales began in December 2017.


During the midterm elections in November, the situation changed as Maryland voters decided to legalize the sale of marijuana for adult use.


According to a press release from MMCC, the regulation of medical marijuana will transition from the Medical Marijuana Commission to the Alcohol and Tobacco Commission in 2023, as mandated by a law passed by voters.


According to an announcement, Chairperson Tiffany Randolph will step down on December 31st.


In the past five years, commission members and staff have established Maryland as a model for medical marijuana programs and have helped the state prepare for the transition to an expanded medical and adult-use market," said Randolph in a statement.


According to a press release, Dr. C. Obi Onyewu, current Vice-Chair of MMCC, will serve as acting Chair as Maryland launches a recreational marijuana market.


Starting from July 1, 2023, it will be legal for adults aged 21 and above to consume and possess up to 1.5 ounces of marijuana.


The true retail market may not begin until 2024 or 2025.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit
Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit
Several vape manufacturers and distributors, including Shenzhen Smoore Technology Co. Ltd., Smoore International Holdings, 3Win Corp., Jupiter Research LLC, Canna Brand Solutions, and Greenlane Holdings Inc., have filed motions seeking dismissal of consumer claims in consolidated antitrust litigation in the U.S. District Court for the Northern District of California.
Events
Feb.24
Canadians visiting Mexico warned of stricter penalties for bringing e-cigarettes or vaping devices
Canadians visiting Mexico warned of stricter penalties for bringing e-cigarettes or vaping devices
Canadians traveling to Mexico should avoid packing e-cigarettes or vaping devices, citing Canada’s travel advisory warning that tourists have been banned from bringing such items into Mexico since 2025. The advisory says customs officials could confiscate the items upon arrival and travelers could be fined or detained.
Feb.09 by 2FIRSTS.ai
Manchester’s Cheetham Hill Hosts 54 Vape Shops Across Two Streets
Manchester’s Cheetham Hill Hosts 54 Vape Shops Across Two Streets
Cheetham Hill in Greater Manchester has become one of the UK’s most concentrated vape retail clusters, with 54 e-cigarette shops operating along two adjacent streets following a police crackdown on counterfeit goods in the area.
Feb.21
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Brazil’s MPF and Anvisa sign pact to intensify enforcement against vapes
Brazil’s MPF and Anvisa sign pact to intensify enforcement against vapes
Brazil’s Federal Public Prosecutor’s Office (MPF) and health regulator Anvisa signed a cooperation protocol to strengthen enforcement against electronic smoking devices (DEFs) and expand health-risk awareness campaigns.
Feb.03 by 2FIRSTS.ai
BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
British American Tobacco reported FY2025 revenue of £25.61 billion, down 1.0% on a reported basis but up 2.1% at constant currency. New Categories revenue rose 5.5%, with category contribution increasing 77%. Smokeless products accounted for 18.2% of group revenue.
Feb.12